Merck KGaA Company Profile (NASDAQ:MKGAY)


Merck KGaA logoMerck KGaA is a Germany-based company engaged in the pharmaceutical industry. The Company operates through four business segments: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnological origin. The Consumer Health division comprises the over-the-counter products for preventive health care and self-treatment of minor ailments. The Merck Serono and Consumer Health divisions form together the Company's Pharmaceutical business sector. The Merck Millipore division comprises the activities of the Millipore Corporation. The Performance Materials division consists mainly of the Liquid Crystals and Pigments & Cosmetics business units. The Company operates through numerous subsidiaries, including Peer+ BV, AZ Electronic Materials (AZ), BioControl Systems Inc and Ormet Circuits Inc., a material supplier for the semiconductor industry.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MKGAY
  • CUSIP: N/A
  • Web: N/A
  • Market Cap: $51.06 billion
  • Outstanding Shares: 387,729,000
Average Prices:
  • 50 Day Moving Avg: $38.97
  • 200 Day Moving Avg: $36.37
  • 52 Week Range: $31.28 - $42.02
  • Trailing P/E Ratio: 29.99
  • Foreward P/E Ratio: 5.68
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $16.6 billion
  • Price / Sales: 0.91
  • Book Value: $12.06 per share
  • Price / Book: 3.25
  • Dividend Yield: 1.1%
  • EBIDTA: $4.99 billion
  • Average Volume: 8,163 shs.

Frequently Asked Questions for Merck KGaA (NASDAQ:MKGAY)

What is Merck KGaA's stock symbol?

Merck KGaA trades on the NASDAQ under the ticker symbol "MKGAY."

Where is Merck KGaA's stock going? Where will Merck KGaA's stock price be in 2017?

7 brokerages have issued 1 year price objectives for Merck KGaA's stock. Their forecasts range from $57.00 to $73.00. On average, they anticipate Merck KGaA's stock price to reach $65.00 in the next year. View Analyst Ratings for Merck KGaA.

Who are some of Merck KGaA's key competitors?

How do I buy Merck KGaA stock?

Shares of Merck KGaA can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Merck KGaA stock cost?

One share of Merck KGaA stock can currently be purchased for approximately $39.16.

Analyst Ratings

Consensus Ratings for Merck KGaA (NASDAQ:MKGAY) (?)
Ratings Breakdown: 1 Sell Rating, 3 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.29)
Consensus Price Target: $65.00 (65.99% upside)

Analysts' Ratings History for Merck KGaA (NASDAQ:MKGAY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/7/2017HSBC Holdings plcDowngradeHold -> ReduceLowView Rating Details
10/14/2016Bank of America CorpUpgradeNeutral -> BuyN/AView Rating Details
8/12/2016Berenberg BankDowngradeBuy -> HoldN/AView Rating Details
8/10/2016Credit Suisse Group AGUpgradeNeutral -> Outperform$73.00N/AView Rating Details
8/10/2016Jefferies Group LLCReiterated RatingHold$53.00 -> $57.00N/AView Rating Details
7/18/2016BMO Capital MarketsReiterated RatingMarket PerformN/AView Rating Details
5/25/2016DZ Bank AGReiterated RatingBuyN/AView Rating Details
5/19/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/AView Rating Details
5/17/2016Citigroup IncReiterated RatingBuyN/AView Rating Details
4/8/2016Nord/LBReiterated RatingBuyN/AView Rating Details
4/8/2016Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
2/6/2016Goldman Sachs Group IncReiterated RatingNeutral$60.00 -> $56.00N/AView Rating Details
12/1/2015Barclays PLCUpgradeEqual Weight -> Overweight$64.00 -> $66.00N/AView Rating Details
11/17/2015ArgusReiterated RatingBuy$70.00 -> $65.00N/AView Rating Details
10/26/2015Societe GeneraleReiterated RatingNeutralN/AView Rating Details
7/2/2015Piper Jaffray CompaniesReiterated RatingUnderweightN/AView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for Merck KGaA (NASDAQ:MKGAY)
No earnings announcements for this company have been tracked by


Earnings Estimates for Merck KGaA (NASDAQ:MKGAY)
Current Year EPS Consensus Estimate: $6.99 EPS
Next Year EPS Consensus Estimate: $6.89 EPS


Dividend History for Merck KGaA (NASDAQ:MKGAY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Merck KGaA (NASDAQ:MKGAY)
No insider trades for this company have been tracked by


Headline Trends for Merck KGaA (NASDAQ:MKGAY)
Latest Headlines for Merck KGaA (NASDAQ:MKGAY)
DateHeadline logoBillionaire George Soros Is Warming Up to This Big Pharma Stock. Should You? - May 19 at 6:58 PM logoMerck KgaA Q1 Profit Down, Sales Rise; Backs FY17 Organic Sales Growth View - May 19 at 11:06 AM logo100 Healthy Years - Are Kids Prepared? - May 19 at 11:06 AM logoMerck KgaA Q1 Profit Dips, Adj. EBITDA Rises; Backs FY17 Sales Growth View - May 18 at 8:32 AM logoMerck KGaA Plans Measures For Structural Development Of Its Business Sectors - May 17 at 6:30 PM logoMerck KGaA, Darmstadt, Germany, and Pfizer to Present Data Highlighting Potential of Avelumab in Challenging Cancers at ASCO 2017 - May 17 at 6:30 PM logoShaping Cancer Care Today and Tomorrow: Merck, KGaA, Darmstadt, Germany, to Present New Data from Rapidly Evolving Pipeline at ASCO 2017 - May 17 at 6:30 PM logoTurmoil In Immuno-Oncology - May 15 at 10:25 AM logoKeytruda Gets Hot And Propels Merck: Analysis - May 11 at 7:04 PM logoPfizer : FDA Grants BAVENCIO Approval For Common Type Of Advanced Bladder Cancer - May 10 at 12:28 PM logoMerck KGaA : EC Grants Approval For New Pergoveris Pen For Fertility Treatment - May 10 at 12:28 PM logoHere's Why Vertex Pharmaceuticals Incorporated Gained 8% in April - May 8 at 6:06 PM logoVWR Funding, Inc. -- Moody's places VWR on review for downgrade - May 5 at 6:50 PM logoMerck KGaA (MKGAY) Receives Consensus Recommendation of "Hold" from Brokerages - May 3 at 9:58 AM logoMerck KGaA : MKGAY-US: Dividend Analysis : May 03rd, 2017 (record date) : By the numbers : May 2, 2017 - May 2 at 4:39 PM logoMerck Raises Dividend - April 28 at 7:29 PM logoFresenius Shows Biotech How To Get The Deals Done - April 26 at 11:44 PM logoFresenius and Merck Stocks Top DAX on Biosimilars Deal - April 25 at 7:26 AM logoMerck KGaA (MKGAY) Stock Rating Lowered by HSBC Holdings plc - April 7 at 8:05 PM logoMerck KGaA (MKGAY) Receives Average Rating of "Hold" from Analysts - April 7 at 6:51 PM logoBeiGene, Another Beijing Venture In Cancer Therapy - March 25 at 6:13 PM logoMerck KGaA : FDA Approves First Treatment For Rare Form Of Skin Cancer - March 24 at 12:08 AM logoFDA OKs Merck KGaA and Pfizer's avelumab for rare type of skin cancer - March 23 at 7:06 PM logoMerck KGaA (MRK) Given a €105.00 Price Target by Goldman Sachs Group Inc Analysts - March 16 at 8:45 AM logoMerck KGaA (MRK) – Analysts’ Weekly Ratings Changes - March 13 at 5:57 PM logoPfizer And Merck Go For An Even Longer Throw Of The Javelin - March 11 at 12:52 AM logoMerck KGaA (MRK) Given “Neutral” Rating at JPMorgan Chase & Co. - March 10 at 2:45 PM logoMerck KGaA (MRK) PT Set at €109.00 by Commerzbank Ag - March 9 at 12:21 PM logoMerck KgaA Q4 Profit More Than Doubles; Proposes Higher Dividend - March 9 at 8:44 AM logoMerck KgaA Q4 Profit Soars, Sees Stable Earnings In FY17; Stock Dips - March 9 at 8:44 AM logoFDA accepts EMD Serono's BLA for avelumab for urothelial carcinoma; action date August 27 - February 28 at 6:41 PM logoMerck KGaA teams up with Domain Therapeutics in immuno-oncology - January 23 at 10:10 AM logoAstra's Mystic Mystery And Other Surprises In Store - January 18 at 7:05 PM logoMerck KGaA And Palantir Launch New Healthcare Acceleration Partnership - January 13 at 5:07 AM logoVertex to collaborate with Germany's Merck in oncology - January 12 at 12:10 AM logoGerman Merck Unveils Its Secret Weapon - January 10 at 7:27 PM logoMerck Acquires BioControl to Strengthen Position in Food Safety Testing - January 4 at 7:23 PM logoMerck KGaA Acquires BioControl Systems - January 4 at 7:23 PM logoRoche Expands Distribution Agreement With Merck KgaA's Life Science Business - December 1 at 9:37 AM logoRoche expands distribution partnership with Merck KGaA - December 1 at 9:37 AM logoEvotec and Merck KGaA team up to discover new therapeutic targets - November 30 at 11:21 AM logo8:19 am Merck KGaA and Pfizer (PFE) announce that the FDA has accepted for Priority Review MKGAY's BLA for avelumab - November 29 at 2:51 PM logoFDA accepts avelumab BLA under Priority Review for rare type of skin cancer - November 29 at 2:51 PM logoQuintilesIMS forms collaboration with major drug firms to better understand real-world uses of cancer treatments - November 22 at 10:21 AM logoGermany's Merck Lifts Full Year Guidance After Sigma-Aldrich Boosts Sales - November 16 at 9:51 AM logoMerck KgaA Lifts FY16 Earnings View As Q3 Results Climb, Stock Up - November 15 at 9:52 AM logoMerck KGaA, Darmstadt, Germany's Phase IIb ADDRESS II Results Confirm Potential of Atacicept as a Candidate Therapy for SLE - November 14 at 10:18 AM logo8:01 am Merck KGaA announces the results of the ADDRESS II Phase IIb, multicenter study on atacicept in patients with systemic lupus erythematosus; primary endpoint not met in overall study population - November 14 at 10:18 AM logoMerck KGaA, Darmstadt, Germany, Presents Phase II Data on the Safety and Efficacy of Atacicept at the 2016 ACR/ARHP Annual Meeting - November 2 at 9:42 AM logoMerck KGaA, Darmstadt, Germany Partners with American Cancer Society to Address Cancer in Women - November 1 at 6:27 PM



Merck KGaA (MKGAY) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by Staff